Efficacy and safety of PCSK9 inhibitor for dyslipidemia
Not Applicable
- Conditions
- refractory dyslipidemia
- Registration Number
- JPRN-UMIN000023483
- Lead Sponsor
- Sekino Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
Doctor's decision not to register to this regimen
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DL, HDL, T-cho(Pre, 1M, 3M, 6M, 1Y, 2Y)
- Secondary Outcome Measures
Name Time Method Pre, 6M, 1Y, 2Y 1) FMD 2) carotis echo 3) ABI Pre, 3M, 6M, 1Y, 2Y 4) U-alb, U-type IV collagen 5) cystatin C, ox-LDL, Lp (a), EPA/AA, Apo A1, B, E, TG 6) Cr,eGFR 7) complications
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link PCSK9 inhibition to reduced oxidative stress in refractory dyslipidemia patients?
How does evolocumab compare to statins in LDL-C reduction for high-risk cardiovascular patients with treatment-resistant dyslipidemia?
Which biomarkers predict evolocumab response in Sekino Hospital's EVOLUTION trial for refractory dyslipidemia?
What adverse events are associated with long-term PCSK9 inhibitor use in Japanese patients with cardiovascular disease?
How do PCSK9 inhibitors like evolocumab influence atherosclerotic plaque progression compared to ezetimibe in refractory hyperlipidemia?